# A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.

> **NCT07161687** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 50 (estimated)

## Conditions studied

- Hemophilia A or B

## Interventions

- **DRUG:** Marstacimab

## Key facts

- **NCT ID:** NCT07161687
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-30
- **Primary completion:** 2030-04-11
- **Final completion:** 2030-04-11
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07161687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07161687, "A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07161687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*